Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -12.05%1.87B | -9.19%1.8B | -1.49%1.84B | -0.42%8.04B | 14.12%2.06B | 17.32%2.13B | -1.78%1.98B | -23.25%1.87B | 5.62%8.08B | -18.97%1.8B |
| Cost of revenue | -12.67%1.7B | -10.02%1.63B | -1.49%1.69B | -1.75%7.35B | 14.61%1.87B | 15.62%1.95B | -2.93%1.81B | -25.16%1.72B | 6.45%7.49B | -20.57%1.63B |
| Gross profit | -5.40%171.03M | -0.31%169.82M | -1.51%152.29M | 16.28%690.35M | 9.36%183.95M | 39.44%180.8M | 12.37%170.35M | 7.21%154.62M | -3.92%593.68M | 0.77%168.21M |
| Operating expense | 27.17%37.42M | 85.19%39.11M | 7.72%23.19M | 23.92%107.88M | 52.31%37.18M | 40.18%29.42M | 2.70%21.12M | 2.05%21.53M | 12.63%87.06M | -8.28%24.41M |
| Selling and administrative expenses | 27.32%37.92M | 84.14%39.84M | 4.18%23.62M | 24.68%113.7M | 55.57%38.98M | 28.24%29.78M | 1.40%21.63M | 5.04%22.68M | 13.99%91.2M | -7.23%25.05M |
| -Selling and marketing expense | 175.17%399K | 4.28%390K | 11.68%478K | 13.84%1.6M | -0.77%389K | -56.46%145K | 15.79%374K | 20.90%428K | 30.42%1.4M | 20.62%392K |
| -General and administrative expense | 26.60%37.52M | 85.55%39.45M | 4.03%23.15M | 24.84%112.11M | 56.47%38.59M | 29.47%29.64M | 1.18%21.26M | 4.78%22.25M | 13.76%89.8M | -7.57%24.66M |
| Total other operating income | 39.72%503K | 41.02%722K | -61.98%438K | 40.54%5.82M | 178.91%1.8M | -83.89%360K | -33.33%512K | 132.26%1.15M | 52.63%4.14M | 63.71%645K |
| Operating profit | -11.73%133.62M | -12.41%130.71M | -3.00%129.1M | 14.97%582.47M | 2.06%146.77M | 39.30%151.38M | 13.89%149.23M | 8.09%133.09M | -6.28%506.62M | 2.48%143.81M |
| Net non-operating interest income (expenses) | -140.07%-658K | -234.94%-1.04M | -23.32%1.58M | -18.63%6.56M | 128.15%4.09M | -14.88%1.64M | -63.46%770K | -7.84%2.06M | 380.23%8.06M | -27.86%1.79M |
| Non-operating interest income | -15.62%4.22M | -19.62%3.38M | 21.07%6.56M | 5.21%20.15M | 15.73%5.52M | 1.85%5.01M | -6.89%4.2M | 9.45%5.42M | 61.48%19.15M | -5.81%4.77M |
| Non-operating interest expense | 45.14%4.88M | 28.65%4.42M | 48.26%4.98M | 22.01%12.17M | -52.08%1.43M | 12.66%3.36M | 42.61%3.43M | 23.66%3.36M | 10.98%9.98M | 114.57%2.97M |
| Total other finance cost | ---- | ---- | ---- | 27.44%1.41M | ---- | ---- | ---- | ---- | -6.81%1.11M | ---- |
| Net investment income | ||||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | -146.01%-1.11M | 2,632.35%2.79M | 53.96%2.21M | 7.86%4.23M | -85.63%283K | 23.83%2.41M | 108.09%102K | 13.23%1.44M | -13.10%3.92M | 153.08%1.97M |
| Special income (charges) | ||||||||||
| Other non-operating income (expenses) | ||||||||||
| Income before tax | -15.17%131.85M | -11.75%132.46M | -2.70%132.89M | 14.39%593.26M | 2.43%151.15M | 38.10%155.43M | 13.82%150.1M | 7.86%136.59M | -5.15%518.61M | 2.77%147.57M |
| Income tax | -6.76%36.77M | -16.76%33.34M | -3.52%32.76M | 12.32%151.87M | -11.10%38.44M | 49.48%39.43M | 17.58%40.05M | 7.67%33.95M | -14.01%135.21M | -10.60%43.24M |
| Net income | -18.03%95.08M | -9.93%99.12M | -2.43%100.14M | 15.12%441.39M | 8.03%112.71M | 34.62%115.99M | 12.51%110.05M | 7.93%102.63M | -1.58%383.4M | 9.56%104.33M |
| Net income continuous operations | -18.03%95.08M | -9.93%99.12M | -2.43%100.14M | 15.12%441.39M | 8.03%112.71M | 34.62%115.99M | 12.51%110.05M | 7.93%102.63M | -1.58%383.4M | 9.56%104.33M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -18.03%95.08M | -9.93%99.12M | -2.43%100.14M | 15.12%441.39M | 8.03%112.71M | 34.62%115.99M | 12.51%110.05M | 7.93%102.63M | -1.58%383.4M | 9.56%104.33M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -18.03%95.08M | -9.93%99.12M | -2.43%100.14M | 15.12%441.39M | 8.03%112.71M | 34.62%115.99M | 12.51%110.05M | 7.93%102.63M | -1.58%383.4M | 9.56%104.33M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | -17.94%0.0741 | -9.92%0.0772 | -2.38%0.078 | 13.33%0.34 | 8.00%0.0878 | 34.58%0.0903 | 12.47%0.0857 | 7.83%0.0799 | 0.00%0.3 | 14.83%0.0813 |
| Diluted earnings per share | -17.94%0.0741 | -9.92%0.0772 | -2.38%0.078 | 13.33%0.34 | 8.00%0.0878 | 34.58%0.0903 | 12.47%0.0857 | 7.83%0.0799 | 0.00%0.3 | 14.83%0.0813 |
| Dividend per share | 0 | 19.26%0.1028 | 14.01%0.096 | 3.41%0.2335 | 0 | 0.0631 | 0.00%0.0862 | 2.18%0.0842 | 20.30%0.2258 | 0.0572 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.